Please login to the form below

Not currently logged in
Email:
Password:

pembrolizumab

This page shows the latest pembrolizumab news and features for those working in and with pharma, biotech and healthcare.

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Pembrolizumab combination therapy is a promising treatment option for these patients who currently have very few. ... We have, as ever, worked collaboratively with NHS England and NICE to ensure the value of pembrolizumab in combination with chemotherapy

Latest news

More from news
Approximately 24 fully matching, plus 256 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H).

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Last year, the FDA approved Merck’s Keytruda (pembrolizumab) as a first-line agent alongside chemotherapy for metastatic NSCLC on data showing the chance of cancer progression was cut in half.

  • Deal Watch January 2017 Deal Watch January 2017

    patent dispute over Keytruda (pembrolizumab) therefore avoiding a court appearance scheduled for later in the year. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics